ADARx Pharmaceuticals, Inc. Common Stock

ADRX

시가총액 US$18.9억

소개: Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.